Effects of Aquamin F on Osteoarthritis of the Knee

Inclusion Criteria * Subjects aged 35 to 75, male or female * Subjects diagnosed with symptomatic moderate to severe osteoarthritis of the knee according to the modified criteria of the American College of Rheumatology17, 18 * Subjects who present with osteoarthritis of the knee as judged by symptoms and disabilities detectable through published, validated questionnaires or previous diagnosis by a physician. * Subjects who are symptomatic with daily or near daily pain and stiffness from osteoarthritis. * Subjects with screening WOMAC Osteoarthritis Index total score (transformed score) of not more than 75. * Subjects with ability to comprehend and complete the questionnaires and forms. * Subjects whose schedules permit clinic evaluations every four weeks. * Subjects who are willing to stop taking calcium supplements, if any, and to restrict consumption of high calcium foods to 600 mg (two dairy serving) per day * Subjects with a high probability of compliance with study procedures and test article consumption. * Subjects willing and able to follow protocol guidelines and schedules, and complete diaries. * Subjects who are likely to abstain from taking unauthorized supplements or participating in any other clinical trial or experimental treatment during this trial * Subjects with normal gastrointestinal digestion and absorption. Exclusion Criteria * Subjects suffering from inflammatory arthritis, gout, pseudogout, Paget's disease, seizure disorder, insulin dependent diabetes mellitus, uncontrolled hypertension, unstable cardiovascular disease, active hepatic or renal disease, active cancer and/or HIV infection. * Subjects who are non-ambulatory or bedridden due to osteoarthritis. * Subjects who are dependent on prescription drugs to control pain. * Subjects on any other clinical trial or experimental treatment in the past 3 months * Subjects who are pregnant, lactating, or at risk of becoming pregnant. * Subjects who have received: * Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) within 48 hours prior to study enrollment. * Intramuscular or systemic corticosteroid injection within 4 weeks prior to study enrollment. * Intra-articular corticosteroid injection within 2 months prior to study enrollment. * Intra-articular hyaluronic acid injection within 4 months prior to study enrollment.